Trial of New Alzheimer's Drug Slated for Early 2023
  (7/1/22)
The biotech behind this product candidate differentiates itself from competitors with its approach to developing selective antibody therapies, noted an Argus Research Co. report. More >

MedTech Co.'s Shares Maneuver Higher on Q1 Revenue Growth
Source: Streetwise Reports  (7/1/22)
Shares of personalized, member-focused healthcare solutions company Accolade Inc. traded 29% higher after the company reported financial results for Q1/23 highlighting a 44% YoY increase in revenue and significant improvements in adjusted gross margin. More >

Chen's Top Picks for Q3
Source: Streetwise Reports  (6/30/22)
Need to know where to go in these turbulent times? Asset manager Chen Lin has some ideas with his top picks for the third quarter. More >

BioNTech and Pfizer Secure $3.2B Vaccine Order from US Govt.
Source: Streetwise Reports  (6/30/22)
Shares of BioNTech SE traded 5% higher after the company together with its partner Pfizer Inc. reported that the two firms have agreed to provide 105 million 30 µg, 10 µg and 3 µg new doses of the SARS-Co-V2 vaccine to the U.S. government in a contract valued at $3.2 billion. The agreement includes a provision allowing the U.S. government to purchase up to an additional 195 million doses, which if exercised would increase the grand total to 300 million doses. More >

New Alzheimer's Drug Shows Promise as Monotherapy
  (6/29/22)
Athira Pharma Inc.'s treatment with this small molecule alone resulted in improvements related to both primary and secondary endpoints, indicating pharmacological activity, noted a BTIG report. More >

Dental & Animal Health Supplier Posts 10% Yearly Sales Gains
Source: Streetwise Reports  (6/29/22)
Shares of Patterson Companies Inc. traded 11% higher after the dental supply and animal health products distributor reported Q4/22 and FY/22 financial results highlighting a 9.9% increase in annual sales and an expansion in operating margins. More >

Small Cap Joins With Japan Pharma to Advance Next Generation Cancer Treatment
Source: Streetwise Reports  (6/28/22)
Shares of Sutro Biopharma Inc. traded 21% higher after the company announced it entered into a global collaboration agreement with Japan's Astellas Pharma to advance three novel immunostimulatory antibody-drug conjugates. More >

Drug Co. to Conduct P1/2a Trial of Psilocybin in Depression
  (6/27/22)
In this trial, slated to commence next quarter, the biopharma will test the efficacy of its version of the psychedelic compound in this mental health indication, noted a ROTH Capital Partners report. More >

Approval Likely of New Gel for Skin Condition, Analyst Says
  (6/27/22)
The biotech developer of this gene therapy is preparing to launch it commercially in the U.S. and pursuing approval of it elsewhere in the world, noted an H.C. Wainwright & Co. report. More >

EU Biopharma Co. Makes $247M Bid for US Oncology Co.
Source: Streetwise Reports  (6/27/22)
Epizyme Inc. shares traded 55% higher today after the company reported that it agreed to be acquired by Ipsen S.A. of France for $1.45 per share along with a contingent value right of $1.00 per share. More >

Gene Therapy Co. Releases Data From Huntington's Study
Source: Streetwise Reports  (6/23/22)
Shares of uniQure N.V. traded 26% higher after the company released 12-month treatment data from the low-dose cohort in its Phase 1/2 Huntington's disease clinical trial. More >

PE Firm to Take Health Tech Co. Private in $1.1B Deal
Source: Streetwise Reports  (6/22/22)
Shares of healthcare technology and services firm Convey Health Solutions Holdings Inc. traded 138% higher after the company reported it received a proposal from majority shareholder TPG Inc. to take the company private. TPG has offered to buy all outstanding shares in Convey that it does not already own for $10.50 per share in cash. More >

Biopharma Co. Doses First MM Patient in Ph. 1 Leukemia Trial
Source: Streetwise Reports  (6/22/22)
Shares of Biomea Fusion Inc. traded 14% higher after the company reported it dosed the first Multiple Myeloma patient in its Phase 1 COVALENT-101 r/r acute leukemia trial. More >

Results of Dermatitis Clinical Trial Due This Summer
  (6/21/22)
Enrollment is now done for VYNE Therapeutics Inc.'s Phase 2a trial following encouraging Phase 1b efficacy data, noted an H.C. Wainwright & Co. report. More >

New Positive Data Seem to Support Drug Label Expansion
  (6/21/22)
Checkpoint Therapeutics Inc., the biopharma behind this late-stage monoclonal antibody for metastatic cutaneous squamous cell carcinoma, could use the new trial results to seek approval in the locally advanced presentation of this cancer, too, noted a Ladenburg Thalmann report. More >

New Drug for Heart Failure on Path to Approval, Analyst Says
  (6/20/22)
The U.S. Food and Drug Administration will likely approve Cytokinetics Inc.'s small molecule in Q1/23, during which its PDUFA date is scheduled, noted an H.C. Wainwright & Co. report.
More >

NFL Player Teams With Biopharma Co. to Help SCD Patients
Source: Streetwise Reports  (6/17/22)
Shares of Global Blood Therapeutics Inc. traded 12% higher after the company reported it has teamed up with New York Jets running back Tevin Coleman and his family to promote education and to offer hope and support to families affected by sickle cell disease. More >

Dispute Between Biopharma Cos. To Be Resolved by Sept. 30
  (6/16/22)
The arbitration court extended the original deadline for a decision in this case of an alleged breach of contract between TRACON Pharmaceuticals Inc. and I-Mab Biopharma, noted an H.C. Wainwright & Co. report. More >

Biotech Co. Advances 3 New Clinical Stage Assets
  (6/16/22)
Ocugen Inc.'s new diverse product candidates include a COVID vaccine, a gene therapeutic for retinitis pigmentosa, and a cell therapy to prevent osteoarthritis, noted a ROTH Capital Partners report. More >

Healthcare Tech Firm Improves Earnings and Cash Flow in Q3/22
  (6/14/22)
These changes earned Reliq Health Technologies Inc. an upgrade in overall rating by independent investment research and advisory firm, Jefferson Research. More >

Investors Gain a Breath of Fresh Air From Ph. 3 CS Trial Results
Source: Streetwise Reports  (6/13/22)
Optinose Inc. shares traded 40% higher after the company reported positive top-line data from its Phase 3 ReOpen2 Trial of XHANCE for use in treating chronic sinusitis without nasal polyps. More >

Biopharma Co.'s New Diabetes Drug Candidate Shows Promise
  (6/10/22)
Biomea Fusion Inc.'s new menin inhibitor is soon to begin clinical human trials after it restored glycemic control and outperformed the standard of care, in animal models. More >

New Drug for Peanut Allergy in Toddlers Shown Safe and Effective
  (6/10/22)
The response rate to DBV Technologies SA's drug patch in the recent Phase 3 clinical trial was statistically significant, which bodes well for the company as there is currently no approved therapy for children with this condition. More >

Biotech Co.'s Shares Soar on Ph. 2 Hematology Trial Results
Source: Streetwise Reports  (6/10/22)
Cogent Biosciences Inc. shares traded 70% higher after the firm reported positive clinical data from Part 1 of its ongoing Phase 2 APEX trial evaluating bezuclastinib in patients with advanced systemic mastocytosis (AdvSM), a severe hematologic disorder. More >

Good Chance FDA Will Greenlight Solution for Dry Eye Disease
  (6/9/22)
Approval would be positive news for Aldeyra Therapeutics Inc. given the market for the indication is large and underserved, noted a BTIG report. More >